From a clinical standpoint, since Smo gene silencing effectively inhibits tumor cell growth and promotes apoptosis, this strategy has the potential to be developed as a new treatment approach for NKTCL. The gene discussed is SMO; the disease is extranodal nasal NK/T cell lymphoma.